Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial
Key Takeaways
- Ozempic carries a boxed warning against use in patients with personal or family history of medullary thyroid carcinoma or MEN-2
- Pregnancy, severe hypersensitivity to semaglutide, prior pancreatitis, and severe gastroparesis are firm exclusions
- Relative cautions include eating disorder history, advanced age, diabetic retinopathy, and active gallbladder disease
- Drug interactions exist around delayed gastric emptying; insulin and sulfonylurea doses often need reduction
- Even patients who meet eligibility criteria may need dose modification based on tolerance, comorbidities, and concomitant therapy
Direct answer
No, not anyone can take Ozempic. The drug has a boxed warning excluding patients with personal or family medullary thyroid carcinoma history or MEN-2. It is contraindicated in pregnancy and in patients with severe hypersensitivity to semaglutide. Prior pancreatitis, severe gastroparesis, active eating disorder, and active gallbladder disease are generally treated as relative contraindications. Beyond these categorical exclusions, individual eligibility depends on concomitant medications, kidney function, age, and tolerance.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The boxed warning
- Absolute contraindications
- Relative contraindications
- Drug interactions
- Special populations
- Side effect profile
- How prescribers screen
- Contrary view: are we screening too aggressively
- Decision framework
- FAQ
- Sources
The boxed warning
The Ozempic label carries a boxed warning, the FDA's strongest safety designation. The warning excludes use in patients with:
- Personal history of medullary thyroid carcinoma (MTC)
- Family history of MTC (first-degree relative)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
The basis is animal data: rodent studies showed dose-dependent thyroid C-cell tumors, including malignant ones. Human surveillance data through 2025 have not confirmed elevated MTC risk in semaglutide users. The boxed warning persists because MTC is rare, the rodent finding was robust, and a true human signal would take years to emerge in observational data.
Patients who meet the boxed-warning criteria are excluded categorically. This is one of the few medical decisions in GLP-1 prescribing where there is no clinical discretion: the answer is no.
Absolute contraindications
Beyond the boxed warning, the following are treated as absolute exclusions by most reputable prescribers:
| Condition | Reason |
|---|---|
| Pregnancy | Animal teratogenicity data; discontinue 2 months before planned conception |
| Severe hypersensitivity to semaglutide | Documented anaphylaxis or angioedema in prior exposure |
| Personal/family MTC, MEN-2 | Boxed warning (see above) |
| Active pancreatitis | Acute event in progress; therapy contraindicated |
Relative contraindications
Relative contraindications are situations where the prescriber weighs risk and benefit case by case. Most reputable prescribers decline in these scenarios; some proceed with extra monitoring.
Prior pancreatitis. Acute pancreatitis was reported in semaglutide trials at low absolute rates (under 0.5%) but at increased relative frequency compared with placebo. Patients with prior pancreatitis carry a baseline elevated risk; a recurrence is harder to manage and harder to attribute. Most prescribers decline.
Severe gastroparesis. Semaglutide further delays gastric emptying. In patients with established gastroparesis, this can produce profound nausea, vomiting, and inability to maintain hydration. Compounded peptide products without titration data carry similar risk. Decline is the standard recommendation.
Active gallbladder disease. Rapid weight loss is a known trigger for gallstone formation. Semaglutide therapy is associated with elevated rates of cholelithiasis and acute cholecystitis. Patients with active gallbladder symptoms typically defer GLP-1 initiation.
Eating disorder history. The appetite-suppressing mechanism can worsen restrictive eating, purging behavior, or binge-restrict cycling. Patients with active or recent eating disorders are generally not appropriate candidates. Patients with remote history (over 5 years remission, stable) can sometimes be considered with mental health support coordination.
Diabetic retinopathy. Rapid glycemic improvement can transiently worsen retinopathy. Patients with moderate to severe nonproliferative or proliferative retinopathy should have ophthalmologic clearance and may need slower titration.
Active suicidal ideation. Some post-marketing reports raised concern about psychiatric side effects, though the FDA review through 2024 did not establish a causal link. Patients with active suicidal ideation are generally stabilized before starting therapy.
Drug interactions
Ozempic does not have many direct pharmacokinetic interactions. The main interaction mechanism is delayed gastric emptying, which slows the absorption of oral medications.
Insulin and sulfonylureas. Combined use increases hypoglycemia risk. Dose reduction is typically required when starting semaglutide in patients on insulin or a sulfonylurea (glipizide, glyburide, glimepiride).
Oral contraceptives. The label notes potential reduced absorption, particularly during dose escalation. Effective contraception is recommended; backup methods (condoms) during titration are common practice for patients of reproductive age.
Levothyroxine. Delayed absorption can alter TSH stability. Patients on chronic levothyroxine may need TSH rechecks 6-8 weeks after starting semaglutide and after dose changes.
Warfarin. Altered food absorption affecting vitamin K intake plus the gastric-emptying effect can shift INR. Closer INR monitoring during dose changes is common.
Oral medications with narrow therapeutic windows. Phenytoin, digoxin, lithium, cyclosporine, and similar drugs warrant closer level monitoring during semaglutide initiation.
Special populations
Adolescents. Ozempic is not approved for patients under 18. Wegovy is FDA-approved for adolescents 12 and older with BMI at or above the 95th percentile for age and sex (approval June 2023). Off-label Ozempic prescribing in adolescents is rare and typically limited to pediatric endocrinology specialists.
Older adults. No firm upper age limit. Patients over 75 have less trial data and tend to experience more pronounced gastrointestinal side effects, sarcopenia risk, and dehydration risk. Lower starting doses, slower titration, and closer follow-up are common.
Kidney disease. Mild to moderate chronic kidney disease is not an exclusion; semaglutide is not primarily renally cleared. The concern is dehydration from GI side effects worsening renal function. End-stage renal disease patients have limited data; many prescribers decline or refer to nephrology.
Liver disease. Mild to moderate hepatic impairment is acceptable. Severe hepatic impairment has limited data; most prescribers proceed cautiously.
Bariatric surgery patients. Post-bariatric patients can take semaglutide. Considerations include altered gastric anatomy affecting tolerance, nutritional status, and risk of dehydration with persistent nausea.
Side effect profile
Common side effects (>5% incidence in trials):
- Nausea (15-44% depending on dose)
- Diarrhea (8-30%)
- Vomiting (5-24%)
- Constipation (5-24%)
- Abdominal pain (5-20%)
- Decreased appetite (5-10%)
- Headache (5-14%)
Most side effects diminish as patients tolerate the medication. Dose titration (starting at 0.25 mg weekly and increasing every 4 weeks) is designed to minimize GI symptoms.
Serious side effects requiring discontinuation:
- Pancreatitis (rare but documented)
- Severe hypoglycemia (in patients on insulin or sulfonylureas)
- Acute kidney injury from dehydration
- Severe allergic reactions (anaphylaxis, angioedema)
- Significant retinopathy progression
- Severe gallbladder events requiring cholecystectomy
How prescribers screen
A typical intake screening process covers:
- Personal and family history of MTC or MEN-2 (direct exclusion if positive)
- Personal history of pancreatitis, severe gastroparesis, or eating disorder
- Pregnancy status, breastfeeding status, contraception use
- Active diabetic retinopathy and ophthalmology follow-up
- Concomitant medications (insulin, sulfonylureas, warfarin, oral contraceptives, narrow-window drugs)
- Kidney function (baseline creatinine, eGFR)
- Liver function (baseline LFTs in some protocols)
- Psychiatric history including suicidal ideation
- BMI and comorbidity profile
Telehealth platforms vary in screening rigor. Reputable platforms use structured questionnaires that flag exclusions automatically and route flagged patients to clinician review. Lower-quality platforms may rely on patient self-attestation alone, which increases the risk of missed contraindications.
Contrary view: are we screening too aggressively
Some clinicians argue that the relative contraindication list has expanded beyond evidence. Two examples:
Eating disorder history. Categorical exclusion of all patients with any eating disorder history may miss the substantial subgroup who would benefit from appetite regulation. Patients with stable remote history of binge eating disorder, for instance, have shown reduced binge frequency on GLP-1 therapy in small studies. A more nuanced screening (active vs. remote, type of disorder, current treatment status) may better serve these patients.
Diabetic retinopathy. The transient retinopathy worsening risk is real but small. Excluding all retinopathy patients from GLP-1 therapy may deny benefit to patients whose cardiovascular and metabolic risk profile favors treatment. Ophthalmologic co-management is often sufficient.
The counter: liability incentives push prescribers toward broad exclusion. A patient who develops a serious complication after being prescribed despite a relative contraindication creates substantial legal and clinical exposure. The asymmetric risk encourages aggressive screening.
The reasonable position: keep the boxed warning and absolute contraindications inviolable. Apply relative contraindications with case-by-case judgment, documented shared decision-making, and willingness to coordinate with specialists.
Decision framework
Boxed warning positive (MTC or MEN-2 personal/family history): Do not take Ozempic under any circumstance. Discuss non-GLP-1 alternatives with your clinician.
Pregnant, breastfeeding, or trying to conceive within 2 months: Defer or discontinue. Discuss with your obstetric provider.
Prior pancreatitis or severe gastroparesis: Most prescribers will decline. If you and your clinician agree to proceed, expect close monitoring.
Active eating disorder: Stabilize first with eating-disorder specialist care. Revisit GLP-1 candidacy only after sustained remission and specialist clearance.
On insulin, sulfonylureas, warfarin, or narrow-window drugs: You can typically take semaglutide, but dose adjustments and closer monitoring are required.
Otherwise eligible: Proceed with standard titration, side-effect monitoring, and regular follow-up.
FAQ
Can anyone take Ozempic? No. The boxed warning excludes patients with personal or family medullary thyroid carcinoma history or MEN-2. Pregnancy, severe hypersensitivity, and severe pancreatitis or gastroparesis are also exclusions.
Why is there a boxed warning for thyroid cancer? Rodent studies showed dose-dependent thyroid C-cell tumors. Human surveillance has not confirmed an elevated MTC risk in patients through 2025, but the FDA maintains the warning as a precaution.
Can I take Ozempic if I had pancreatitis? Most clinicians decline. Acute pancreatitis was reported in trials and recurrence risk in patients with prior episodes is elevated.
Can pregnant women take Ozempic? No. Discontinue at least 2 months before planned conception.
Does Ozempic interact with other medications? Yes. Insulin, sulfonylureas, oral contraceptives, warfarin, levothyroxine, and narrow-window drugs require attention. Delayed gastric emptying affects oral absorption.
Can patients with kidney disease take Ozempic? Mild to moderate kidney disease is not an exclusion. End-stage renal disease has limited data.
Can patients with eating disorders take Ozempic? Generally no for active or recent disorders. Remote, stable history may allow consideration with specialist coordination.
Is there an age limit for Ozempic? Adults 18+. Patients over 75 generally need slower titration and closer follow-up. Pediatric use is off-label; Wegovy is the approved option for adolescents 12+ with severe obesity.
Sources
- FDA. Ozempic Prescribing Information, Boxed Warning Section. Current revision 2025.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM. 2023.
- FDA Adverse Event Reporting System (FAERS). Semaglutide Post-Marketing Surveillance Summary, 2024.
- American Diabetes Association. Standards of Medical Care in Diabetes, 2025.
- American Association of Clinical Endocrinologists. Clinical Practice Guideline: Pharmacotherapy of Obesity. 2024.
- Endocrine Society. GLP-1 Receptor Agonists in Practice: Guidance Update. 2024.
- American College of Gastroenterology. GLP-1 Agonist Use in Patients with Gastroparesis: Position Statement. 2024.
- American College of Obstetricians and Gynecologists. Pregnancy and GLP-1 Therapy. Committee Opinion, 2024.
- American Academy of Ophthalmology. Diabetic Retinopathy and Rapid Glycemic Change: Clinical Statement. 2023.
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM. 2016 (SUSTAIN-6).
- National Eating Disorders Association. GLP-1 Medications and Eating Disorder History: Provider Guidance. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends connects patients to independent licensed clinicians and U.S.-based pharmacies. Eligibility for any medication is determined by a clinician after evaluation. We do not directly diagnose, prescribe, or dispense.
Compounded Medication Notice. Compounded semaglutide is prepared by a state-licensed 503A pharmacy in response to an individual prescription. It is not FDA-approved, has not undergone the same review as commercial products, and is not interchangeable with Ozempic or Wegovy.
Results Disclaimer. Side effect frequencies cited reflect average rates in clinical trials and may differ in individual practice. Patient experience depends on dose, titration, comorbid conditions, and concomitant medications.
Trademark Notice. Ozempic and Wegovy are trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are trademarks of Eli Lilly and Company. FormBlends is independent of these manufacturers.